Nitric oxide-releasing medications and colorectal cancer risk: the framingham study.
The major sources of human exposure to nitric oxide (NO) are medicinal nitrovasodilators that release NO into the vasculature. Experimental NO-donating aspirin also releases NO in a similar manner, and is a potent in vitro inhibitor of colon cancer. The effects of nitrovasodilators on the risk of colorectal cancer was studied in the Framingham Heart and Offspring studies among 145 cases of colorectal cancer and 433 matched controls. Eleven percent of controls reported currently using nitroglycerine or other long-lasting nitrates. In conditional logistic regression analysis, the odds ratio (OR) for colorectal cancer associated with nitrovasodilator use was 1.2 (95% confidence interval [CI] 0.6, 2.2). In subgroup analysis, the OR was 0.7 (95% CI 0.2, 2.2) in aspirin users and 1.6 (95% CI 0.8, 3.2) in subjects not taking aspirin. These data indicate that NO does not change the risk of colorectal cancer.